$NVRO

Nevro Corp

  • NEW YORK STOCK EXCHANGE INC.
  • Health Technology
  • Medical Specialties
  • Manufacturing
  • Surgical and Medical Instrument Manufacturing

PRICE

$43.37 -

Extented Hours

VOLUME

433,293

DAY RANGE

42.9 - 44.12

52 WEEK

41.74 - 182.45

Join Discuss about NVRO with like-minded investors

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Healthcare Alkermes ($ALKS) announced that it received notices of partial termination in respect of two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson Acadia Pharmaceuticals Inc ($ACAD) 3Q EPS ($0.09) vs est. ($0.26) on sales $131.6Mm vs est. $127.8Mm, says narrows FY Nuplazid sales guide to $480-500Mm Castle Biosciences ($CSTL) 3Q EPS ($0.47) vs est. ($0.41) on revs $23.5Mm vs est. $23Mm; says on track to achieve FY total revs guide of $89-93Mm vs est. $91.9Mm Clover Health ($CLOV) Q3 revs $427.2M vs est. $413.1M, adj EBITDA ($102.3M) vs est. ($99.5M); sees FY revs $1.42B-$1.47B vs est. $1.44B Curaleaf holdings ($CURLF) Q3 revenue $317M vs est. $328.3M, adj EBITDA $71M vs est. $92.1M; remains on track to generate revenue within lower end of $1.2B-$1.3B annual guidance range; said the acquisition of Tryke Companies reported earlier today bolsters its position in NV, AZ, UT and will be immediately accretive to margins and cash flow Fluidigm Corp ($FLDM) 3Q EPS ($0.18) vs est. ($0.22) on revs $28.5Mm vs est. $30Mm; says undertaking review of various options including with regard to strategic alternatives Invitae Corporation ($NVTA) Q3 adj EPS ($0.81) vs est. ($0.71) on revenue $114.4M vs est. $126.5M driven by billable volume 296k (+89% YoY); now sees FY revenue $450M-$475M, from $475M-$500M and below est. $484.5M Mirati Therapeutics, Inc. ($MRTX) 3Q EPS ($1.55) vs est. ($2.89) on revs $71.8Mm Nevro Corp. ($NVRO) Q3 EPS loss ($1.44) vs. est. loss (-$0.87); Q3 rev $93.2M vs. est. $91.59M; sees Q4 revs $94M-$98M Oak Street Health, Inc. ($OSH) Q3 EPS loss (-$0.49) vs. est. loss (-$0.42); Q3 revs $388.7M vs. est. $356.7M; The Company cared for approximately 100,500 risk-based patients, representing 76% of its total patients; adjusted EBITDA was $(64.3M), compared to $(22.8M) YoY SI-BONE ($SIBN) Q3 EPS ($0.48) vs est. ($0.42) on revenue $22.3M vs est. $22.5M, lowered FY21 revenue view to $89M-$90M from $92M-$94M (vs est. $92.7M) as uncertainty surrounding Covid-19’s impact on elective procedures and healthcare infrastructure remains Shockwave Medical ($SWAV) Q3 EPS $0.05 vs. est. loss (-$0.06); Q3 revs $65.2M vs. est. $61.2M; sees FY21 revenue $227M-$228M vs. est. $223.43M, which represents 235% to 236% growth YoY SmileDirectClub, Inc. ($SDC) shares fall -23%; 3Q EPS ($0.23) vs est. ($0.13) on revs $138Mm vs est. $$181Mm; guides FY revs $630-650Mm vs est. $757Mm Tactile Systems ($TCMD) shares fell -12%; 3Q EPS ($0.17) vs est. $0.12 on revs $52.5Mm vs est. $57.4Mm; sees FY revs +9-10% or $203.5M-$206M from $216.3M-$224.5M, below est. +18.7% Merck ($MRK) said the U.S. government will buy 1.4 million additional courses of their COVID-19 pill, molnupiravir, for about $1 bln and that the U.S. has now committed to purchase a total of about 3.1 million courses of molnupiravir for about $2.2 billion Haemonetics ($HAE) Q2 adj EPS $0.60 vs. est. $0.61; Q2 revs $239.9M vs. est. $241.4M; lowers FY22 adj EPS view to $2.40-$2.65 from $2.60-$3.00 and narrows its FY22 revenue view to up 13%-17% from up 13%-18% Technology, Media & Telecom Bandwidth Inc. ($BAND) Q3 adj EPS $0.25 vs. est. $0.08; Q3 revs $130.6M vs. est. $125.3M; guides Q4 EPS loss (15c-11c) vs. est. loss (-$0.01); sees Q4 revs $115.7M-$120.7M vs. est. $125.5M 3D Systems ($DDD) 3Q adj EPS $0.08 vs est. $0.05 on revs $156.1Mm vs est. $144.8Mm; guides FY adj gr mgn 41-43% vs est. 42.7% Five9 Inc. ($FIVN) 3Q adj EPS $0.28 vs est. $0.23 on revs $154.3Mm vs est. $146.8Mm; guides 4Q revs $164.5-165.5mm vs est. $157.8Mm, sees 4Q adj EPS $0.36-0.37 vs est. $0.34; sees FY revs $$600.5-601.5Mm vs est. $585.2Mm and adj EPS $1.09-1.10 vs est. $1.02 Instructure Holdings, Inc. ($INST) 3Q EPS ($0.10) vs est. $0.14 on revs $107.2Mm vs est. $101.1Mm; sees 4Q revs $106.9-107.9Mm vs est. $104.1Mm; guides FY revs $401.7-402.7Mm vs est. $397.4Mm, sees FY adj EBITDA $143.6-144.6Mm vs est. $130Mm Luminar Technologies, Inc. ($LAZR) shares rise 50%; said at the NVIDIA GTC conference that its lidar solution has been selected to be part of the sensor suite in the NVIDIA DRIVE Hyperion autonomous vehicle reference platform. This AI vehicle computing platform accelerates development of autonomous consumer vehicles with planned production starting in 2024. New Relic ($NEWR) Q2 adj EPS loss (10c) vs. est. loss (13c); Q2 revs $196M vss. Est. $182.21M; cuts FY22 adj EPS loss view to (60c)-(54c) from (52c)-(49c) while boosts FY22 revenue view to $778M-$782M from $730M-$735M (est. $736.8M) National CineMedia ($NCMI) Q3 EPS loss (19c) vs. est. loss (13c); Q3 revs $31.7M vs. est. $41.24M; Q3 adjusted OIBDA improved to negative $8.2 million for the third quarter of 2021 from negative $11.2 million for the third quarter of 2020 Roblox ($RBLX) shares rise 29%; Q3 EPS (13c) vs est. (14c) on bookings $637.8M vs est. $636.5M, revenue $509.5M, avg DAUs 47.3M vs est. 46.6M, hours engaged 11.2B (+28% YoY), avg booking per DAU $13.49 Sanmina ($SANM) Q4 adj EPS $0.95 vs. est. $0.99; Q4 revs $1.64B vs. est. $1.7B; sees Q1 adj EPS 90c-$1.00 vs. est. $1.01; sees Q1 revs $1.6B-$1.7B below consensus $1.76B Square Space ($SQSP) Q3 EPS 4c vs est. 14c on revenue $201M vs est. $205.2M; sees Q4 revenue $203M-$206M vs est. $205.2M, raised annual revenue forecast to $780M-$783M from $772M-$780M (est. $778.4M) and unlevered FCF to $117M-$122M from $102M-$116M TripAdvisor ($TRIP) 3Q adj EPS $0.16 vs est. $0.24 on revs $303Mm vs est. $304.4Mm; avg monthly unique users on branded websites rose to about 76% of 2019 comparable period; says CEO will step down during 2022 Vuzix Corporation ($VUZI) Q3 EPS loss (-$0.13), in-line with ests; Q3 revs $3.02M vs. est. $3.79M; General and Administrative expense for the three months ended September 30, 2021 was $3.1 million versus $1.6 million for the comparable 2020 period Xperi Holding Corporation ($XPER) 3Q adj EPS $0.53 vs est. $0.34 on res $219.4Mm vs est. $215.4Mm; guides FY revs $870-890Mm vs est. $882.2Mm Zynga ($ZNGA) 4Q EPS ($0.04) vs est. $0.07 on revs $704.7Mm vs est. $666Mm, qtrly bookings $668Mm +6%, average mobile DAUs 38Mm +21%, qtrly avg mobile MAUs 183Mm +120%; sees FY revs $2.78B vs est. $2.81B, sees FY bookings $2.814B

64 Replies 12 👍 15 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Monday, November 8, 2021 Futures Up/Down % Last Dow 72.00 0.20% 36,287 S&P 500 4.25 0.09% 4,694 Nasdaq 9.00 0.06% 16,360 U.S. futures are looking to open at new record highs (again) after Washington passed a smaller form of its highway, broadband and other infrastructure improvement spending deal this weekend, as the $1 trillion infrastructure bill passed through Congress on Friday. A very important week of economic data coming up with monthly CPI, PPI inflation data mid-week. Crypto assets rising to records ahead of the inflation reports as Bitcoin up 8% nearing $66K, Ethereum record highs up over 6% above $4,700, Litecoin tops $200, up over 5.75% as crypto assets surging again. Tech futures underperform following weakness in Tesla (TSLA) after its CEO Elon Musk on Saturday asked his 62.5 million followers on Twitter in a poll if he should sell 10% of his Tesla stock. The world’s richest person had previously said he could face a “massive” tax bill this year as he has to exercise a large number of stock options coming due next year. In Asian markets, The Nikkei Index fell -100 points to 29,507, the Shanghai Index rose 0.2% to just under 3,500, and the Hang Seng Index declined 100 points to 24,763. In Europe, the German DAX is down about -0.1% at 16,035, while the FTSE 100 is flat holding just above 7,300. Last week the S&P 500, Nasdaq and Dow notched their fifth straight weekly advances (longest streak for the S&P since Aug 2020); for the week, the S&P 500 rose 2%, the Dow added 1.42%, the Nasdaq gained 3.05% and the Russell 200o over 6%. The Nasdaq 100 (QQQ) notched its 10th winning session in a row on Friday while the S&P 500 scored another record high on Friday and booked a week of solid gains following a strong U.S. jobs report and positive data for Pfizer’s experimental pill against COVID-19, which helped boost travel and other economic reopen sectors. The news kept the run going for equities after investors earlier in the week digested the Federal Reserve’s decision to start reducing its monthly bond purchases put in place to support the economy. Market Closing Prices Yesterday The S&P 500 Index gained 17.47 points, or 0.37%, to 4,697.53 The Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95 The Nasdaq Composite climbed 31.28 points, or 0.20%, to 15,971.59 The Russell 2000 Index advanced 34.65 points, or 1.44% to 2,437.08 Events Calendar for Today No major U.S. economic data Earnings Calendar: Earnings Before the Open: ATRO, AXSM, BKI, COTY, DS, EDIT, EHTH, GATO, GTES, HLIO, KOS, LINC, NERV, NSSC, RDNT, RDUS, RETA, THS, TTD, USFD, VAC, VUZI, WOW, ZIXI Earnings After the Close: ACAD, AEIS, AEL, AMBC, AMC, AMPH, AMRS, APEI, APPF, APTS, ASUR, ATER, AVEO, BAND, BRP, CARA, CBT, CHRS, CLRS, CLOV, CSSE, CSTL, CXW, DDD, DOOR, ENV, FIVN, FLDM, FRPT, FSK, FTK, GOSS, HIL, IEA, IFF, IIN, INST, IPAR, JKHY, KERN, LMND, LOTZ, MRC, MRTX, MWA, NCMI, NEWR, NNI, NVRO, NVTA, OCIUL, OUST, PRA, PRI, PRIM, PYPL, RBLX, REAL, SANM, SCOR, SDC, SNCR, SPCE, SWSP, SWAV, SWX, TCMD, TREX, TRIP, TWO, XNCR, ZIOP, ZNGA Other Key Events: Credit Suisse 30th Annual Healthcare Conference, 11/8-11/11 (virtual) JPMorgan Global Consumer, Retail & Luxury Conference, 11/8-11/21 (virtual) EEI Financial Conference, 11/7-11/9 (virtual) REITWorld 2021 Annual Conference, 11/9-11/12 (virtual) Macro Up/Down Last Nymex 1.22 82.49 Brent 1.09 83.83 Gold -0.50 1,818.50 EUR/USD -0.0002 1.1564 JPY/USD 0.05 113.46 10-Year Note +0.032 1.485% World News China’s export growth moderated slightly to 27.1% yoy in October, above the 22.8% consensus expectation, implying a sequential gain of 2.6% in October (a modest slowdown from +3.0% in September) despite electricity constraints in October. At the same time, imports rose 20.6% yoy in October, missing expectations of a 26.2% surge, but fell 3.2% sequentially in October (vs. -0.7% in September). As a result of the far bigger growth in exports over imports, the monthly trade surplus rose further to a record high of $84.5bn in October, supporting the appreciation of the Chinese yuan in October, even as China’s economy has slowed down sharply in recent months. China’s trade surplus with the United States was $40.75 billion in October based on customs data showed on Sunday, down from $42 billion in September. For the first ten months of the year, the surplus was $320.67 billion – Reuters Highway, broadband and other infrastructure improvement spending deal this weekend, as the $1 trillion infrastructure bill passed through Congress on Friday and among parts of the deal, allows for $7.5 billion spending for building out a network of electric vehicle chargers and another $7.5 billion for low or zero-emission buses and ferries. Sector News Breakdown Consumer Tesla Inc ($TSLA) CEO Elon Musk on Saturday asked his 62.5 million followers on Twitter in a poll if he should sell 10% of his Tesla stock. The world’s richest person had previously said he could face a “massive” tax bill this year as he has to exercise a large number of stock options coming due next year. “Note, I do not take a cash salary or bonus from anywhere. I only have stock, thus the only way for me to pay taxes personally is to sell stock,” Musk said on Twitter on Saturday. Rivian Automotive ($RIVN) raises IPO price range to $72.00-$74.00 from $57.00-$62.00. Separately, Barron’s noted Rivian Automotive (RIVN) is set to go public this coming week at a market value that could exceed that of Honda Motor (HMC) despite having sold just a handful of vehicles, with a market cap around $64 billion Haverty’s (HVT) announces special cash dividend, quarterly cash dividend, and additional authorization under stock repurchase program Peloton ($PTON) has halted hiring across all departments effective immediately, CNBC reported late Friday, a day after it slashed its full-year outlook amid slowing momentum for its fitness products Coty ($COTY) agrees to sell additional partial stake in Wella to KKR in exchange for about 56% of Preferred Coty shares owned by KKR Marriott Vacations ($VAC) Q3 adjusted EPS $1.60 vs. est. $1.42; Q3 revs $1.05B vs est. $1.07B; said occupancies at our resorts this quarter were very strong despite the Delta variant and contract sales were within 3% of 2019 levels, driving 25% sequential growth in Adjusted EBITDA Energy China’s crude oil imports plunged in October to the lowest since September 2018, as large state-owned refiners withheld purchases because of rising prices while independent refiners were restrained by limited quotas to import. The world’s biggest crude oil importer brought in 37.8 million tonnes last month, data from the General Administration of Customs showed on Sunday, equivalent to 8.9 million barrels per day (bpd). – Reuters FirstEnergy ($FE) agrees to sell a 19.9% stake in its three regulated transmission businesses to Brookfield Asset Management (BAM) for $2.4B Financials Berkshire Hathaway Inc ($BRK/A) said that global supply chain disruptions kept a lid on its ability to generate profit; Q3 operating profit rose 18% but missed analyst forecasts amid goods shortages that crimped consumer spending; net income, meanwhile, fell 66%, reflecting lower gains from stock holdings such as Apple Inc and Bank of America Corp. Alleghany ($Y) mentioned positively in Barron’s saying shares should not be overlooked noting under CEO Weston Hicks, Alleghany has used a similar strategy to create an attractive, smaller-scale version of Warren Buffett’s Berkshire Hathaway ($BRK.A) R. Berkley ($WRB) announced that its Board of Directors has declared a special cash dividend on its common stock of $1.00 per share to be paid on December 22 to stockholders of record at the close of business on December 7 Healthcare Cannabis stocks rose late Friday after Marijuana Moment reported a fresh Republican-led attempt to legalize marijuana. The States Reform Act led by Rep. Nancy Mace (R-SC) is still in the preliminary stage, and a final version is expected to be filed later this month. As U.S. health authorities expand use of the leading Covid-19 vaccines, researchers investigating heart-related risks linked to the shots are exploring several emerging theories, including one centered on the spike protein made in response to vaccination. Researchers aren’t certain why the messenger RNA vaccines, one from Pfizer Inc. ($PFE) and partner BioNTech SE ($BNTX) and the other from Moderna Inc., are likely causing the inflammatory heart conditions myocarditis and pericarditis in a small number of cases. – WSJ https://on.wsj.com/3mQqCVY Alcon ($ALC) has acquired Ivantis, developer and manufacturer of the novel Hydrus Microstent, a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery for $475M in upfront consideration Genetron Holdings ($GTH) has formed a strategic partnership with oncology laboratory solution provider NeoGenomics (NEO) to drive global oncology drug research and development. Industrials & Materials Boeing ($BA) directors agreed to a $237.5 million settlement of claims that they turned a blind eye to safety issues related to 737 Max jetliners whose crashes have cost the company more than $20 billion, according to court documents Blade Air Mobility ($BLDE) is bringing ride-sharing to helicopters-just don’t call it the Uber ($UBER) of the sky. The stock can take off without that comparison, Barron’s reported. Blade Air Mobility is a less risky way to invest in the eVTOL future, though certainly not risk-free BHP is close to a deal to sell its controlling interest in two Australian coal mines to Stanmore Resources Ltd. ($STMRF) for ~$1.25B, the Wall Street Journal reports. Technology, Media & Telecom New Oriental Education & Technology ($EDU), Gaotu Techedu ($GOTU), and Tal Education ($TAL) shares all rising over 20% after the WSJ reported that China plans to issue more than a dozen licenses that would allow companies to offer after-school tutoring. The report said Gaotu Techedu (GOTU) and Yuanfudao, a unit of Tencent ($TCEHY), have held talks about resuming tutoring to students in the ninth grade and below https://on.mktw.net/3EVcxg5 Trinseo ($TSE) has begun work to explore the divestiture of its Styrenics businesses and plans to launch a formal sales process in Q1 of 2022. The scope of this potential divestiture is expected to include the Feedstocks and Polystyrene reporting segments as well as the company’s 50% ownership of Americas Styrenics AU Optronics ($AUOTY) reports October revenue of NT$30.38B (+18.1% Y/Y, -9.9% M/M); the total panel area shipment reached around 2.08 million square meters in October 2021, down by 4.3% month-over-month. ChipMOS ($IMOS) reports October revenue of $82.3M (-2.3% M/M; +10.7% Y/Y).

96 Replies 15 👍 9 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Healthcare Moderna ($MRNA) Q2 EPS $6.46 vs. est. $6.04; Q2 revs $4.4B vs. est. $4.28B; expects dose capacity for its covid-19 vaccine in fy 2021 to be between 800 mln and 1 bln doses; advance purchase agreements signed for expected product sales of $20 bln in 2021, including sales already recorded in 6 months ended June 30; signed agreements for $12 bln worth of sales for covid-19 vaccine in 2022, option for about $8 bln more; continue to expect $450 mln -$550 mln of capital investments for 2021 Cigna ($CI) Q2 adj EPS $5.24 vs. est. $4.96; Q2 revs $43.13B vs. est. $41.31B; pharmacy customer base at Q2 grew to 101.9M, an organic increase of 3.1M year to date; total medical customer base at Q2 was 17M, an increase of 279,000 customers YTD; Q2 profit overall fell -16% hurt by higher medical costs; backs year EPS but ups its rev guidance to at least $170B from $166B Nevro ($NVRO) slides after withdrawing FY forecast on COVID-19 concerns and guided Q3 sales between $90M-$93M which is below analyst estimates of $114.7M Regeneron Pharma ($REGN) phase 3 Trial of Libtayo combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Abiomed ($ABMD) Q1 adj EPS $1.10 vs. est. $1.05; Q1 revs $252.6M vs. est. $240.91M; raises FY22 revenue view to $1.03B-$1.05B from prior $990M-$1.03B (22%-24% growth); expects its fiscal year 2022 non-GAAP operating margin to be in the range of 24% to 26% Amedisys ($AMED) announces new $100M share repurchase program; Q2 adj EPS $1.69 vs. est. $1.67; Q2 revs $564.2M vs. est. $566.19M; guides 2021 adj EPS $6.37-$6.49 vs. est. $6.96; sees 2021 adj net service revenue $2.23B-$2.245B. Evolent Health ($EVH) 2Q EPS ($0.11) vs est. ($0.04) on revs $222.1Mm vs est. $216.9Mm; guides 3Q revs $215-230Mm vs est. $217.7Mm, sees FY revs $870-900Mm vs est. $870.8Mm; announces agreement to acquire Vital Decisions outstanding equity interests for aggregate price up to $130Mm, says transaction is accretive to EBITDA/share before synergies McKesson ($MCK) Q1 adj EPS $5.56 vs. est. $4.15; Q1 revs $62.7B vs. est. $59.99B; raises FY22 adj EPS view to $19.80-$20.40 from prior view $18.85-$19.45 (est. $19.23) 1life Healthcare, Inc. ($ONEM) Q2 EPS loss (-$0.30) vs. est. loss (-$0.20); Q2 revs $120.4M vs. est. $115.7M; sees Q3 revs $113M-$120M vs. est. $118M; sees year revs $475M-$485M vs. est. $482.3M; Membership count as of quarter-end was 621,000 compared to 475,000, a 31% increase; Adjusted EBITDA was positive $6.9 million, or 6% of net revenue Sarepta Therapeutics ($SRPT) Q2 non-GAAP EPS loss (-$1.52) vs. est. loss (-$1.26); net product sales for q2 reached $141.8 mln, a 27% increase over same quarter of prior year; raises full-year product revenue guidance by nearly $30 mln to between $565 mln to $575 mln Tandem Diabetes ($TNDM) 2Q revs $172.1Mm vs est. $143.4Mm; guides FY sales $670-685Mm vs est. $637Mm; guides FY adj EBITDA mgn about 15% vs est. 13.5% Industrials & Materials Albemarle ($ALB) Q2 adj EPS $0.89 vs. est. $0.83; Q2 revs $773.9M vs. est. $788.6M; qtrly lithium net sales of $320.3 mln increased $36.6 mln yoy primarily driven by higher volumes; full-year 2021 net sales guidance improved vs previous guidance primarily due to increased lithium sales, improving catalysts trends – sees year sales $3.3B-$3.4B vs. est. $3.24B Hillenbrand ($HI) 3Q adj EPS $0.85 vs est. $0.76 on revs $695Mm; guides 4Q adj EPS $0.82-0.92 vs est. $0.85, sees 4Q revs $713-738Mm vs est. $709.1Mm Maxar Technologies ($MAXR) 2Q EPS $0.60 vs est. $0.14 on revs $473Mm vs est. $441.5Mm Summit Materials ($SUM) 2Q EPS $0.48 vs est. $0.52 on revs $618.5Mm vs est. $647.1Mm; no change to FY guide Valvoline ($VVV) Q3 adj EPS $0.55 vs. est. $0.45; Q3 revs $792M vs. est. $745.32M; Q3 retail Services system-wide same-store sales grew 40.5%; Q3 same-store sales rose 27%; sees FY sales growth 25%-26% and FCF $250M-$270M Media & Telecom Fox Corp. ($FOXA) Q4 adj EPS $0.65 vs. est. $0.57; Q4 revs $2.89B vs. est. $2.75B; raises semi-annual dividend to 24c; cable network programming reported quarterly segment revenues of $1.40B, an increase of $128M; affiliate revenues increased 10% with 16% growth at the television segment and 6% growth at the cable network programming segment in q4 Roku Inc. ($ROKU) Q2 EPS 52c vs est. 13c on revs $645M vs est. $618.4M, average rev per user $36.46 (+46% YoY), active accounts 55.1M vs est. 55.8M; at midpoint of Q3 guidance, sees revs $675M-$685M vs est. $645M, gross profit $315M-$325M, adj EBITDA $60M-$70M, net income (-$3M)-$7M, anticipates sequential increases in operating expenses in 2H from investments in headcount, product development, and sales & marketing Technology Amdocs Ltd. ($DOX) 3Q adj EPS $1.35 vs est. $1.18 on revs $1.066B vs est. $1.06B; guides 4Q adj EPS $1.13-1.19 vs est. $1.28, sees 4Q revs $1.065-1.105B vs est. $1.087B Booking Holdings ($BKNG) 2Q adj EPS ($2.55) vs est. ($2.04) on revs $2.2B vs est. $1.9B, encouraged by sequential improvement in booking trends with 2Q room nights +59% vs 1Q; said in in q2, we saw the first sequential increase in the number of properties on booking.com and lowest number of properties coming off of our platform since the onset of the covid-19 pandemic DXC Technology ($DXC) Q1 adj EPS $0.84 vs. est. $0.74; Q1 revs $4.14B vs. est. $4.11B; Q2 guidance falls short of views but backs year EPS view $3.45-$3.65 vs. est. $3.56 and backs FY22 revenue view $16.6B-$16.8B (est. $16.74B); Bookings of $4.6 billion and book-to-bill ratio of 1.12x in Q1 FY22 Electronic Arts ($EA) Q1 EPS $0.71 vs. est. $0.62; Q1 net bookings $1.336B vs. est. $1.28B; sees Q2 EPS roughly $0.36 vs. est. $1.07; sees Q2 net bookings $1.725B vs. est. $1.62B; raises FY22 EPS view to $1.58 from $1.34 and ups FY21 bookings view to $7.4B from $7.3B Fastly Inc. ($FSLY) shares fall -18%; Q2 adj EPS ($$0.15) vs est. ($0.17) on revs $85.03M vs est. $85.7M, sees Q3 EPS loss (21c)-(18c) vs est. (18c) on revs $82M-$85M vs est. $97.9M, and forecasts FY EPS (65c)-(57c) vs est. (43c) on revs $340M-$350M vs est. $382.5M GoDaddy ($GDDY) Q2 EPS $0.27 vs. est. $0.32; Q2 revs $931.3M vs. est. $919.7M; total bookings of $1.055B, up 12.7% year over year, or 10.6% on a constant currency basis; Domains revenue of $436.7 million, up 18.2% yoy; Hosting and presence revenue of $318.5 million, up 9.0% yoy; Business applications revenue of $176.1 million, up 21.8% yoy; sees year revs $3.75B, in-line HubSpot ($HUBS) 2Q adj EPS $0.43 vs est. $0.32 on revs $310.8Mm vs est. $296Mm; guides 3Q adj EPS $0.42-0.44 vs est. $0.39, sees 3Q revs $325-327Mm vs est. $318.7Mm; guides FY revs $1.268-1.272B vs est. $1.244B MercadoLibre ($MELI) Q2 EPS $1.37 vs est. $0.19 on revs $1.7B vs est. $1.48B with commerce revs +96.4% YoY and fintech revs +88.9%; unique active users 75.9M in quarter (+47.4% YoY), total payment volume through Mercado Pago topped $17.5B (+56.3% in USD), gross merchandise volume $7B (+39.2% in USD) Ping Identity ($PING) 2Q adj EPS $0.11 vs est. $0.04 on revs $78.9Mm vs est. $66.1Mm; guides 3Q revs $65-70Mm vs est. $65.1Mm, sees 3Q total ARR $286-288Mm; guides FY revs $278-285Mm vs est. $269.3Mm, sees FY total ARR $304-306Mm Qorvo ($QRVO) Q1 EPS $2.83 vs. est. $2.45; Q1 revs $1.11B vs. est. $1.08B; sees Q2 EPS $3.24 at midpoint vs. est. $3.02; sees Q2 revenue $1.24B-$1.26B vs. est. $1.21B Trimble Inc. ($TRMB) Q2 adj EPS $0.72 vs. est. $0.59; Q2 revs $945.3M vs. est. $867.8M; sees FY21 adj EPS $2.45-$2.65 vs. est. $2.45; sees FY21 adjusted revenue $3.55B-$3.65B vs. est. $3.48B; Q2 annualized recurring revenue (ARR) was $1.35 billion, up 11% yoy Western Digital ($WDC) 4Q adj EPS $2.16 vs est. $1.51 on revs $4.9B vs est. $4.55B; guides 1Q revs $4.9-5.1B vs est. $4.9B, sees 1Q adj EPS $2.25-2.55 vs est. $2.05

76 Replies 14 👍 11 🔥

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Wednesday, August 4, 2021 Futures Up/Down % Last Dow -25.00 0.07% 34,973 S&P 500 -1.25 0.04% 4,413 Nasdaq 11.50 0.08% 15,058 U.S. S&P futures are flat heading into the trading day, looking to build on record highs from Tuesday as positive earnings boost U.S and European stocks while worries over China’s gaming and technology crackdown ease, helping lift those markets. Risk sentiment improves across Asia as Chinese and Hong Kong stocks push higher on tech recovery and solid Caixin PMI data. In Asian markets, The Nikkei Index fell -57 points to 27,854, the Shanghai Index rose 29 points to 3,477 and the Hang Seng Index jumped 231 points to settle at 26,426. In Europe, the German DAX is climbing around 125 points to 15,680, while the FTSE 100 is up 0.4% to 7,135. Chinese Jul Caixin Services PMI beat: 54.9 vs 50.6 consensus. Some also see the spread of the Covid-19 delta variant as delaying rather than stopping the economic recovery. The New York Times reported overnight that the FDA plans to give full approval to Pfizer (PFE) and BioNTech (BNTX) coronavirus vaccine by the start of the next month. Earnings season has been strong with about 87% of S&P 500 companies reporting earnings and revenue beats, according to FactSet. Just under 70% of the S&P 500 now has reported earnings. The S&P 500 closed at record highs with gains in Apple and healthcare stocks, as concerns over a surge in the Delta variant of the coronavirus was put to the back-burner, overshadowed by continued upbeat corporate earnings. Ten of the 11 S&P indexes traded higher, with energy stocks rebounding after getting hit by a dip in oil prices. Market Closing Prices Yesterday The S&P 500 Index gained 35.99 points, or 0.82%, to 4,423.15 The Dow Jones Industrial Average rose 278.24 points, or 0.80%, to 35,116.40 The Nasdaq Composite climbed 80.23 points, or 0.55%, to 14,761.29 The Russell 2000 Index advanced 8.09 points, or 0.36% to 2,223.58 Events Calendar for Today 7:00 AM ET MBA Mortgage Applications Data 8:15 AM ET ADP Employment Change for July…est. 695K 9:45 AM ET Markit Composite PMI, July-F 9:45 AM ET Markit Services PMI, July-F 10:00 AM ET ISM Non-Manufacturing Services PMI for July…est. 60.5 10:30 AM ET Weekly DOE Inventory Data Earnings Calendar: Earnings Before the Open: ABC, AEIS, ALE, APO, ASTE, BCOR, BDC, BGCP, BWA, CDW, CLVS, CLH, CLW, CMLS, CRL, CSII, DNOW, DOC, EDIT, EMR, ETR, EXC, FLOW, FUN, GEL, GM, HDSN, HFC, HZNP, IONS, JLL, KHC, LL, MAC, MKL, MPC, MPLX, MTOR, NI, NYT, ODP, RCL, SBGI, SGRY, SITE, SMG, SPR, SUP, TGI, TUP, TXMD, UTHR, VCEL, VMC, WLL Earnings After the Close: ACAD, ACLS, ADPT, ADTN, AGL, ALB, ALL, AMED, ANGI, ANSS, APA, ATO, AXGN, BBSI, BE, BFAM, BKNG, BOOT, CCMP, CDAY, CENX, CHNG, CMP, CPS, DGII, DOX, DVAX, DXC, EA, EGHT, ELF, EMKR, EOG, ETSY, EVH, FLT, FOXA, FSLY, FTDR, GDDY, GNK, HI, HUBS, IAC, INGN, IVR, JACK, LESL, LNC, LPI, LUMN, MAXR, MBI, MCK, MED, MET, MGM, MOD, MRO, MTG, NUS,NVRO, ONEM, PARR, PDCE, $PING, PLYA, QRVO, QTWO, RCII, REGI, RGR, RMAX, RNWK, EOKU, RPD, $RVLV, RYN, SBRA, SMSI, SUM, T$NDM, TPC, TTGT, TVTY, TWNK, TWO, TXG, $UBER, UHAL, VVV, VZIO, WDC, WU, YELL Other Key Events: Jefferies Industrials Conference (virtual), 8/3-8/4 Piper Wealth Management Forum (virtual), 8/3-8/6 Macro Up/Down Last Nymex -0.34 70.22 Brent -0.18 72.23 Gold 3.30 1,813.75 EUR/USD -0.0008 1.1856 JPY/USD 0.13 109.17 10-Year Note +0.008 1.182% Sector News Breakdown Consumer Caesar’s Entertainment ($CZR) Q2 EPS $0.34 vs. est. loss (-$0.26); Q2 revs $2.5B vs. est. $2.27B; Q2 same-store Adjusted EBITDA was $1B versus (-$131M) for the comparable prior-year period; Company posted all-time records in quarterly Adjusted EBITDA and Adjusted EBITDA margin. Denny’s ($DENN) Q2 adj EPS $0.18 vs. est. $0.11; Q2 revs $106.2M vs. est. $98.1M; Q2 domestic system-wide same-store sales decreased 1.2% compared to the equivalent fiscal period in 2019, including a 1.5% decrease at domestic franchised restaurants and a 1.9% increase at company restaurants. Herbalife ($HLF) Q2 adj EPS $1.52 vs. est. $1.29; Q2 revs $1.55B vs. est. $1.57B; Q2 adjusted EBITDA of $262.1M; raises FY21 EPS view to $4.70-$5.10 from $4.65-$5.05 (est. $4.93); sees FY net sales growth to be in a range of 8.5% to 12.5%, lowering the midpoint by 150 basis points compared to prior full year 2021 guidance. Host Hotels ($HST) Q2 adj FFO $0.12 vs. est. $0.04; Q2 revs $649M vs. est. $606.58M; said RevPAR reached nearly $100 for the quarter, which dramatically outperformed consensus RevPAR, with average room rates only 8.4% below our 2019 second quarter rates; not providing year guidance Hyatt ($H) 2Q adj EPS ($1.15) vs est. ($0.85) on comparable system-wide REVPAR $72.47, qtrly total revs $663Mm vs est. $686.9Mm; guides FY net rooms growth more than +6%, sees FY adj SG&A about $240Mm, sees FY CAPEX about $110Mm Energy Devon Energy ($DVN) Q2 adj EPS $0.60 vs est. $0.52 on revs $2.42B vs est. $2.35B, operating cash flow $1.1B, production for the quarter averaged 291k barrels/day; will pay total dividend of 49c/shr (11c fixed + 38c variable), a 44% increase from Q1; sees 3q production 566-594 mboe/d vs est. 564.80 mboe/d Occidental Petroleum ($OXY) Q2 adj EPS 32c vs est. 1c on revs $5.96B vs est. $5.92B, FCF $2B, cash flow from continuing operations $3.3B; said oil and gas results improved from Q1 due to higher commodity prices and sales volumes; executed debt tender offer and repaid over $3B of long-term debt in July ONEOK ($OKE) Q2 EPS $0.77 vs. est. $0.75; Q2 revs $3.39B vs. est. $3.03B; sees 2021 net income, adj earnings before interest, taxes, depreciation, amortization to be above midpoints of ranges provided on April 27, 2021 SunPower ($SPWR) Q2 adj EPS $0.06 vs. est. $0.04; Q2 revs $308.9M vs. est. $327.31M; guides Q3 revs $325M-$375M vs. est. $400.83M; sees Q3 GAAP net loss of $10 to $0 million and MW recognized of 125 MW to 150 MW; Q2 added 13,000 residential customers – residential bookings up 16 percent sequentially, 67 percent year-over-year (YoY) The American Petroleum Institute ($API) showed a draw of 879K barrels of oil for the latest week; gasoline inventories show a draw of 5.75M barrels, distillate inventories show a draw of 717K barrels and Cushing inventories show a build of 659K barrels W&T Offshore ($WTI) Q2 EPS $0.02 vs. est. $0.07; Q2 revs $132.8M vs. est. $122.38M; Q2 Production was 40,888 Boe/d or 3.7 MMBoe, an increase of 3% compared to 39,657 Boe/d in Q1 and down 3% versus 42,037 Boe/d in Q2 of 2020 Financials Assurant Inc. ($AIZ) Q2 operating EPS $2.99 vs. est. $2.45; Q2 revs $2.54B vs. est. $2.39B; continue to expect to grow eps, ex. catastrophes, by 10 to 14 percent for 2021 Fair Isaac ($FICO) Q3 non-GAAP EPS $3.38 vs. est. $2.76; Q3 revs $338M vs. est. $328.3M; Applications revenues, which include the company’s decision management applications and associated professional services, were $133.2 million in the third quarter, compared to $141.5 million in the prior year period, a decrease of 6% Genworth Financial ($GNW) Q2 adj EPS $0.38 vs. est. $0.22; Q2 revs $2.04B vs. est. $1.9B; planned IPO of Enact remains a key strategic objective for Genworth and is subject to market and other conditions, however because the company is in registration and subject to applicable publicity restrictions, is unable to comment further or provide any additional detail at this time. Green Dot ($GDOT) Q2 adj EPS $0.68 vs est. $0.43 on revs $369.4M vs est. $313.2M; sees FY21 adj EPS $2.13-$2.27 vs prev. $2.06-$2.15, revs $1.33B-$1.35B vs est. $1.28B Prudential ($PRU) Q2 adj EPS $3.79 vs. est. $3.02; qtrly book value per common share of $160.31 versus $165.53 per share for year-ago; qtrly adjusted book value per common share of $104.39 versus $92.07 per share for year-ago; qtr end assets under management of $1.730 trillion versus $1.605 trillion for year-ago; now expect to return a total of $11.0B to holders from $10.5B prior Tanger Outlets ($SKT) 2Q core FFO/shr $0.43 vs est. $0.28, portfolio occupancy was 93% on June 30 vs 91.7% on March 31, avg tenant sales productivity was $424/sq ft for 12 months ended June 30 +7.3% yr/yr; guides FY FFO/shr $1.52-1.59 vs est. $1.46 Unum Group (UNM) Q2 adj EPS $1.39 vs. est. $1.11; Q2 revs $2.99B vs. est. $2.96B; Full-year 2021 outlook increased; after-tax adjusted operating income per share now expected to decline 1%-3% relative to full-year 2020, compared to an expected decline of 5%-6% prior Verisk Analytics ($VRSK) Q2 adj EPS $1.17 vs. est. $1.33; Q2 revs $747.5M vs. est. $737.3M; Net cash provided by operating activities was $233.2 million, down 6.5% for the second quarter of 2021. Free cash flow, a non-GAAP measure, was $170.7 million, down 11.5% Healthcare Change Healthcare ($CHNG) shares fell over 7% on a report that the U.S. Dept. of Justice is considering a lawsuit to block the company’s $8B sale to UnitedHealth ($UNH) https://bit.ly/3yA4Etu Option Care Health ($OPCH) 18M share Spot Secondary priced at $20.25 Amgen Inc. ($AMGN) Q2 adj EPS $4.38 vs. est. $4.06; Q2 revs $6.5B vs. est. $6.43B; backs FY21 adj EPS view $16.00-$17.00 vs. est. $16.34; backs FY21 revenue view $25.8B-$26.6B vs. est. $26.04B Amid surge in new COVID-19 infections across U.S., the FDA plans to give full approval to Pfizer (PFE) – BioNTech (BNTX) coronavirus vaccine by the start of the next month, The New York Times reports The FDA classified the recent recall of some of Philips’ (PHG) ventilators as Class 1, or the most serious type of recall, saying the use of these devices may cause serious injuries or death – Reuters CVS Health ($CVS) Q2 adj EPS $2.42 vs. est. $2.06; Q2 revs $72.62B vs. est. $70.11B; raises FY21 adjusted EPS view to $7.70-$7.80 from $7.56-$7.68 (est. $7.66); sees FY21 cash flow from operations $12.5B-$13B DaVita Inc. (DVA) 2Q EPS $2.64 vs est. $2.17; says total US dialysis treatments for 2Q were 7,413497 (avg 95,045/day); guides FY adj EPS $8.80-9.40 vs est. $8.63, sees FY adj op income $1.8-1.875B vs est. $1.816B Inspire Medical ($INSP) 2Q EPS ($0.48) vs est. ($0.64) on revs $53Mm vs est. $43.9Mm; guides FY revs $210-213Mm vs est. $195.9Mm, sees FY gr mgn 85-86%, sees opening 48-52 new US medical centers per qtr for 2H Jazz Pharma ($JAZZ) Q2 adj EPS $3.90 vs. est. $3.42; Q2 revs $751.8M vs. est. $735.62M; reaffirms FY21 non-GAAP EPS view $13.40-$14.70 (est. $14.45) and also back FY21 revenue view $3.020B-$3.180B vs. est. $3.11B; as of June 30, cash, cash equivalents were $891.4 mln, and outstanding principal balance of co’s long-term debt was $7.1 bln

113 Replies 6 👍 6 🔥

profile
@Benlax #droscrew
recently

BIO NVRO are two now on my radar from todays

83 Replies 7 👍 7 🔥

Key Metrics

Market Cap

1.53 B

Beta

1.48

Avg. Volume

760.93 K

Shares Outstanding

35.26 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-03

Next Dividend Date

Company Information

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

CEO: D.Keith Grossman

Website:

HQ: 1800 Bridge Pkwy Redwood City, 94065-1164 California

Related News